HFS
AXSM icon

Hantz Financial Services’s Axsome Therapeutics AXSM Stock Holding History

Hantz Financial Services’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,100
Closed -$88K – 1068
2024
Q1 		$88K Hold
1,100
– – ﹤0.01% 614
2023
Q4 		$88K Hold
1,100
– – ﹤0.01% 609
2023
Q3 		$77K Hold
1,100
– – ﹤0.01% 606
2023
Q2 		$79K Hold
1,100
– – ﹤0.01% 585
2023
Q1 		$68K Hold
1,100
– – ﹤0.01% 595
2022
Q4 		$85K Hold
1,100
– – ﹤0.01% 577
2022
Q3 		$49K Hold
1,100
– – ﹤0.01% 595
2022
Q2 		$42K Buy
+1,100
New +$34.8K ﹤0.01% 602

Other funds holding AXSM

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Hantz Financial Services's AXSM Position: Q2 2024 in Review

Hantz Financial Services sold out of Axsome Therapeutics (AXSM) in Q2 2024, closing a stake of 1,100 shares — an estimated $88K sold.

Hantz Financial Services first reported a position in AXSM in Q2 2022 and held it in 8 quarters. The position peaked at $88K in Q1 2024. 256 funds tracked by Wall St. Rank hold AXSM as of Q2 2024.

  • Hantz Financial Services reported no remaining Axsome Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Hantz Financial Services sold 1,100 Axsome Therapeutics shares in Q2 2024, an estimated $88K.
  • Hantz Financial Services first reported a position in Axsome Therapeutics in Q2 2022 and held it in 8 quarters.
  • Hantz Financial Services's Axsome Therapeutics position peaked at $88K in Q1 2024.
  • 256 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2024.

Based on Hantz Financial Services's 13F filing for Q2 2024, filed 30 Jul 2024.